سعر هيرسبتين 440 مجم فيال باودر للحقن 2024

Herceptin (trastuzumab, F. Hoffmann-La Roche) 440 mg lyophilised powder vial with 20 ml solvent for intravenous infusion: a HER2-targeted humanised monoclonal antibody used for HER2-positive breast cancer and HER2-positive metastatic gastric cancer.

• Early breast cancer whose tumours overexpress HER2 (ECOG 0-1): after surgery and chemotherapy; with paclitaxel or docetaxel after doxorubicin/cyclophosphamide; or with docetaxel and carboplatin.Population: AdultsHoffmann-La Roche Limited (Health Canada-authorized Product Monograph)
• Metastatic breast cancer whose tumours overexpress HER2 (including with pertuzumab and docetaxel in previously untreated HER2-positive metastatic disease).Population: AdultsHoffmann-La Roche Limited (Health Canada-authorized Product Monograph)
• HER2-positive metastatic adenocarcinoma of the stomach or gastro-oesophageal junction, in combination with capecitabine or 5-fluorouracil and cisplatin, in patients without prior anticancer treatment for metastatic disease.Population: AdultsHoffmann-La Roche Limited (Health Canada-authorized Product Monograph)

• Most serious and/or common adverse reactions: cardiac dysfunction, infusion-related reactions, haematotoxicity (particularly neutropenia), infections and pulmonary adverse reactions.General active-ingredient information · European Medicines Agency (EMA) - EPAR product information

• Hypersensitivity to trastuzumab, Chinese hamster ovary (CHO) cell proteins or any ingredient of the formulation or container component.International label, same product · Hoffmann-La Roche Limited (Health Canada-authorized Product Monograph)
• Severe dyspnoea at rest due to complications of advanced malignancy or requiring supplementary oxygen therapy.General active-ingredient information · European Medicines Agency (EMA) - EPAR product information

• Serious warnings: risk of medication errors with trastuzumab emtansine or trastuzumab deruxtecan; cardiotoxicity (ventricular dysfunction, congestive heart failure), highest with anthracyclines; serious and fatal infusion reactions and pulmonary toxicity; embryo-fetal toxicity.International label, same product · Hoffmann-La Roche Limited (Health Canada-authorized Product Monograph)
• The supplied Bacteriostatic Water for Injection contains 1.1% benzyl alcohol, associated with toxicity in neonates and children up to 3 years; in patients hypersensitive to benzyl alcohol, reconstitute with Sterile Water for Injection and use immediately.International label, same product · Hoffmann-La Roche Limited (Health Canada-authorized Product Monograph)

• Anthracyclines (doxorubicin, epirubicin)Increased risk of cardiac dysfunction; trastuzumab may persist in the circulation for up to 7 months, so anthracycline-based therapy should be avoided for up to 7 months after stopping trastuzumab if possible, with careful cardiac monitoring if used.European Medicines Agency (EMA) - EPAR product information

• Can cause fetal harm: post-marketing cases of impaired fetal renal growth/function, intrauterine growth retardation and skeletal abnormalities with oligohydramnios in the second and third trimesters, some with fatal pulmonary hypoplasia. Should not be used in pregnancy unless the potential benefit for the mother outweighs the potential risk to the fetus; monitor for oligohydramnios.International label, same product · Hoffmann-La Roche Limited (Health Canada-authorized Product Monograph)
• Not known whether excreted in human milk; decide whether to discontinue nursing or the drug, considering the elimination half-life of trastuzumab and the importance of the drug to the mother.International label, same product · Hoffmann-La Roche Limited (Health Canada-authorized Product Monograph)

• Trastuzumab: Binds the extracellular domain of the HER2 receptor, inhibiting proliferation of HER2-overexpressing tumour cells and mediating antibody-dependent cellular cytotoxicity.